SCHEMBL2496239

SCHEMBL2496239

Cc1csc2c(O)c(C(=O)NC(C)C(=O)O)c(=O)n(C)c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 6/20 0.41
L3MBTL1 Q9Y468 1/20 0.39
BBOX1 O75936 2/20 0.34
KDM4C Q9H3R0 1/20 0.34
FTO Q9C0B1 1/20 0.34
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 1/20 0.33
HTT P42858 1/20 0.33
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
GRM4 Q14833 2/20 0.32
LMNA P02545 1/20 0.32
PYGL P06737 1/20 0.32
HDAC4 P56524 1/20 0.32
HDAC7 Q8WUI4 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
HDAC9 Q9UKV0 1/20 0.32
HDAC5 Q9UQL6 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2496235 1.00 EGLN1 (0.41) EGLN1L3MBTL1BBOX1KDM4CFTO
SCHEMBL9958193 0.89 EGLN1 (0.41) EGLN1L3MBTL1ALDH1A1KDM4EHTT
SCHEMBL2496013 0.81 EGLN1 (0.63) EGLN1
SCHEMBL2384073 0.76 L3MBTL1 (0.52) EGLN1L3MBTL1BBOX1FTOALDH1A1
SCHEMBL2384074 0.76 L3MBTL1 (0.52) EGLN1L3MBTL1BBOX1FTOALDH1A1
SCHEMBL2493420 0.75 L3MBTL1 (0.48) EGLN1L3MBTL1BBOX1FTOALDH1A1
SCHEMBL2501559 0.74 EGLN1 (0.47) EGLN1KDM4EMEN1KMT2ANPC1
SCHEMBL2498218 0.73 ALDH1A1 (0.51) ALDH1A1KDM4EHTTMEN1KMT2A
SCHEMBL2384050 0.71 L3MBTL1 (0.52) L3MBTL1ALDH1A1KDM4EHTTMEN1
SCHEMBL2384054 0.71 L3MBTL1 (0.52) L3MBTL1ALDH1A1KDM4EHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2150251-B9 THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY AMGEN INC (US) 2013-02-27 EP claimed
EP-2150251-B1 THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY AMGEN INC (US) 2012-06-27 EP claimed
US-8030346-B2 Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity AMGEN INC. (US) 2011-10-04 US claimed
EP-2150251-A1 THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY Amgen, Inc (US) 2010-02-10 EP claimed
US-20090156633-A1 Heterocyclic quinolone derivatives that inhbit prolyl hydroxylase activity AMGEN INC. (US) 2009-06-18 US claimed
WO-2008137060-A1 THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY AMGEN INC. (US) 2008-11-13 WO claimed
EP-2150251-B9 THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY AMGEN INC (US) 2013-02-27 EP disclosed
EP-2150251-B1 THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY AMGEN INC (US) 2012-06-27 EP disclosed
US-8030346-B2 Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity AMGEN INC. (US) 2011-10-04 US disclosed
EP-2150251-A1 THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY Amgen, Inc (US) 2010-02-10 EP disclosed
US-20090156633-A1 Heterocyclic quinolone derivatives that inhbit prolyl hydroxylase activity AMGEN INC. (US) 2009-06-18 US disclosed
WO-2008137060-A1 THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY AMGEN INC. (US) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156633-A1 Heterocyclic quinolone derivatives that inhbit prolyl hydroxylase activity EGLN3, HIF1AN, EGLN2 EGLN1 6/4885L3MBTL1 4234/4885BBOX1 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.